Carcinoma, Pancreatic Ductal
Conditions
Brief summary
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.
Interventions
GENETICMolecular Profiling
Whole Genome Sequencing
Sponsors
University Health Network, Toronto
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a histological or radiological diagnosis of locally advanced or metastatic pancreatic ductal adenocarcinoma. Patients with borderline resectable disease are not eligible. * Patient must have a tumor lesion that is amenable to a core needle biopsy. * Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied. * Patients must be fit enough to safely undergo a tumor biopsy. * Age 18 years or older. * Eastern Cooperative Group (ECOG) performance status of 1 or less. * Life expectancy of greater than 90 days. * Patients must have normal organ and marrow function * Patients must undergo systemic treatment with m-FOLFIRINOX or nab-paclitaxel as a first line standard systemic palliative treatment or combination treatment with m-FOLFIRINOX or nab-paclitaxel with or without other investigational agents within a clinical trial as a first line palliative treatment. * Ability to understand and willing to sign a written informed consent document.
Exclusion criteria
* Patients with one or more contraindications to tumor biopsy. * Patients who have prior systemic treatment (chemotherapy or any other anti-cancer agent) in advanced setting. * Patients who are currently on anti-cancer treatment including chemotherapy. * Patients with known brain metastases. * Patients with advanced PDAC who are going to be treated with gemcitabine monotherapy in advanced setting. * Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing. | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between tumor genomic characteristics and m-FOLFIRINOX response using next generation sequencing. | 5 years |
| Disease control rate achieved by m-FOLFIRINOX | 5 years |
| Disease control rate achieved by nab-paclitaxel | 5 years |
| Duration of response defined as the interval between the first date of complete response or partial response and the earliest date of disease progression or death due to any cause to m-FOLFIRINOX | 5 years |
| Duration of response defined as the interval between the first date of complete response or partial response and the earliest date of disease progression or death due to any cause to nab-paclitaxel. | 5 years |
| Progression free survival defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with m-FOLFIRINOX. | 5 years |
| Progression free survival defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with nab-paclitaxel. | 5 years |
| Overall survival defined as the interval between the date of registration and the date of death of patients treated with m-FOLFIRINOX | 5 years |
| Overall survival defined as the interval between the date of registration and the date of death of patients treated with nab-paclitaxel. | 5 years |
| Percentage of patients with germline BRCA, PALB2 and ATM mutations who might benefit from a personalized treatment strategy such as combination of cisplatin and a PARP inhibition. | 5 years |
| Percentage of patients with somatic DSBR deficiency who might benefit from a personalized treatment strategy such as combination of cisplatin and a PARP inhibitor. | 5 years |
| Percentage of patients who might benefit from immunotherapy (patients with smoking genomic signatures, patients with a hypermutated phenotype, patients with mismatch repair deficiency and patients with tumor neo-antigen expression). | 5 years |
| Percentage of patients with rare but targetable somatic mutations. | 5 years |
| Difference in disease control rate between patients with tumor smoking signature and those without. | 5 years |
| Difference in overall survival between patients with tumor smoking signature and those without. | 5 years |
| Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing. | 5 years |
| Correlation between tumor genomic characteristics and nab-paclitaxel response using the next generation sequencing. | 5 years |
Countries
Canada
Outcome results
None listed